Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.

• Drug: PF-04937319 IR MST
  
  Immediate release material sparing tablet (IR MST) administered as 150 mg with morning meal and 100 mg with lunch
• Drug: PF-04937319 MR 1
  
  Modified release formulation #1 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
• Drug: PF-04937319 MR 2
  
  Modified release formulation #2 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
• Drug: PF-04937319 MR 3
  
  Modified release formulation #3 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST

• Experimental: PF-04937319 IR MST
  
  Reference formulation
  Intervention: Drug: PF-04937319 IR MST
• Experimental: PF-04937319 MR 1
  
  Test MR #1
  Intervention: Drug: PF-04937319 MR 1
• Experimental: PF-04937319 MR 2
  
  Test MR #2
  Intervention: Drug: PF-04937319 MR 2
• Experimental: PF-04937319 MR 3
  
  Test MR #3
  Intervention: Drug: PF-04937319 MR 3

Inclusion Criteria:

• Adults with type 2 diabetes, on stable background metformin therapy either alone or in combination with another oral anti-diabetic agent (OAD) excluding thiazolidinediones (TZDs)

Exclusion Criteria:

• Patients with cardiovascular event within 6 months of screening
• Patients with diabetic complications
• Female subjects who are pregnant or planning to become pregnant
• Subjects with unstable medical conditions (eg, hypertension)